Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1095, Jiefang Avenue, Wuhan, Hubei Province, 430030, China.
Cell Commun Signal. 2024 Sep 10;22(1):436. doi: 10.1186/s12964-024-01792-7.
Endometrial cancer is one of the major gynecological cancers, with increasing incidence and mortality in the past decades. Emerging preclinical and clinical data have indicated its close association with obesity and dyslipidemia. Metabolism reprogramming has been considered as the hallmark of cancer, to satisfy the extensive need of nutrients and energy for survival and growth. Particularly, lipid metabolism reprogramming has aroused the researchers' interest in the field of cancer, including tumorigenesis, invasiveness, metastasis, therapeutic resistance and immunity modulation, etc. But the roles of lipid metabolism reprogramming in endometrial cancer have not been fully understood. This review has summarized how lipid metabolism reprogramming induces oncogenesis and progression of endometrial cancer, including the biological functions of aberrant lipid metabolism pathway and altered transcription regulation of lipid metabolism pathway. Besides, we proposed novel therapeutic strategies of targeting lipid metabolism pathway and concentrated on its potential of sensitizing immunotherapy and hormonal therapy, to further optimize the existing treatment modalities of patients with advanced/metastatic endometrial cancer. Moreover, we expect that targeting lipid metabolism plus hormone therapy may block the endometrial malignant transformation and enrich the preventative approaches of endometrial cancer.
Lipid metabolism reprogramming plays an important role in tumor initiation and cancer progression of endometrial cancer. Targeting the core enzymes and transcriptional factors of lipid metabolism pathway alone or in combination with immunotherapy/hormone treatment is expected to decrease the tumor burden and provide promising treatment opportunity for patients with advanced/metastatic endometrial cancer.
子宫内膜癌是妇科三大恶性肿瘤之一,近几十年来其发病率和死亡率呈上升趋势。新兴的临床前和临床数据表明,它与肥胖和血脂异常密切相关。代谢重编程被认为是癌症的标志,以满足生存和生长所需的大量营养和能量。特别是,脂质代谢重编程引起了研究人员在癌症领域的兴趣,包括肿瘤发生、侵袭、转移、治疗耐药性和免疫调节等。但脂质代谢重编程在子宫内膜癌中的作用尚未完全阐明。本文综述了脂质代谢重编程如何诱导子宫内膜癌的发生和进展,包括异常脂质代谢途径的生物学功能和脂质代谢途径转录调控的改变。此外,我们提出了靶向脂质代谢途径的新治疗策略,并集中讨论了其在增强免疫治疗和激素治疗敏感性方面的潜力,以进一步优化晚期/转移性子宫内膜癌患者的现有治疗方式。此外,我们期望靶向脂质代谢联合激素治疗可能阻断子宫内膜的恶性转化,并丰富子宫内膜癌的预防方法。
脂质代谢重编程在子宫内膜癌的肿瘤发生和癌症进展中起重要作用。单独或联合免疫治疗/激素治疗靶向脂质代谢途径的核心酶和转录因子有望减轻肿瘤负担,为晚期/转移性子宫内膜癌患者提供有前景的治疗机会。